163 related articles for article (PubMed ID: 11119912)
1. Impact of tacrolimus on hyperlipidemia after renal transplantation: a Japanese single center experience.
Manu M; Tanabe K; Tokumoto T; Ishikawa N; Shimizu T; Okuda H; Ito S; Shimmura H; Inui M; Harano M; Shiroyanagi Y; Yagisawa T; Fuchinoue S; Toma H
Transplant Proc; 2000 Nov; 32(7):1736-8. PubMed ID: 11119912
[No Abstract] [Full Text] [Related]
2. Conversion of renal transplant immunosuppression from tacrolimus (FK 506) to cyclosporine: a single center experience.
Ichikura H; Tanabe K; Tokumoto T; Shimuzu T; Ishikawa N; Harano M; Inui M; Manu M; Ito S; Shimmura H; Okuda H; Yagisawa T; Fuchinoue S; Toma H
Transplant Proc; 2000 Nov; 32(7):1733-5. PubMed ID: 11119911
[No Abstract] [Full Text] [Related]
3. Cyclosporine to tacrolimus: effect on hypertension and lipid profiles in renal allografts.
Copley JB; Staffeld C; Lindberg J; Hansen A; Bailey C; Anand R; Van Veldhuisen P
Transplant Proc; 1998 Jun; 30(4):1254-6. PubMed ID: 9636510
[No Abstract] [Full Text] [Related]
4. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus.
Friemann S; Feuring E; Padberg W; Ernst W
Transplant Proc; 1998 Jun; 30(4):1240-2. PubMed ID: 9636504
[No Abstract] [Full Text] [Related]
5. Effect of conversion from cyclosporine to tacrolimus on lipid profiles in renal transplant recipients.
Colak T; Karakayali H; Yagmurdur MC; Moray G
Transplant Proc; 2002 Sep; 34(6):2081-2. PubMed ID: 12270321
[No Abstract] [Full Text] [Related]
6. Lipid profile in renal transplant recipients under various immunosuppressive regimens.
Montagnino G; Tarantino A; Aroldi A; Banfi G; Cesana B; Ponticelli C
Transplant Proc; 1994 Oct; 26(5):2634-6. PubMed ID: 7940821
[No Abstract] [Full Text] [Related]
7. Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report.
Jurewicz WA
Transplant Proc; 1999 Nov; 31(7A):64S-66S. PubMed ID: 10576048
[No Abstract] [Full Text] [Related]
8. Early steroid withdrawal after kidney transplantation.
Yagisawa T; Toma H; Ota K; Tanabe K; Ishikawa N; Tokumoto N; Yaguchi H; Nakada T
Transplant Proc; 1996 Jun; 28(3):1342-5. PubMed ID: 8658686
[No Abstract] [Full Text] [Related]
9. Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation.
Kokado Y; Takahara S; Kyo M; Ichimaru N; Toki K; Wang JD; Okuyama A
Transplant Proc; 1999; 31(1-2):1151-4. PubMed ID: 10083515
[No Abstract] [Full Text] [Related]
10. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study.
McCune TR; Thacker LR II; Peters TG; Mulloy L; Rohr MS; Adams PA; Yium J; Light JA; Pruett T; Gaber AO; Selman SH; Jonsson J; Hayes JM; Wright FH; Armata T; Blanton J; Burdick JF
Transplantation; 1998 Jan; 65(1):87-92. PubMed ID: 9448150
[TBL] [Abstract][Full Text] [Related]
11. Conversion from cyclosporine A to tacrolimus after kidney transplantation due to hyperlipidemia.
Kohnle M; Zimmermann U; Lütkes P; Albrecht KH; Philipp T; Heemann U
Transpl Int; 2000; 13 Suppl 1():S345-8. PubMed ID: 11112029
[TBL] [Abstract][Full Text] [Related]
12. Lipid profile during azathioprine or mycophenolate mofetil combinations with cyclosporine and steroids.
Akman B; Uyar M; Afsar B; Sezer S; Ozdemir FN; Haberal M
Transplant Proc; 2007; 39(1):135-7. PubMed ID: 17275490
[TBL] [Abstract][Full Text] [Related]
13. Effect of tacrolimus in renal transplant recipients with immunoglobulin-A nephropathy.
Suzuki K; Tanabe K; Tokumoto T; Shimizu T; Ishikawa N; Yagisawa T; Honda K; Nihei H; Toma H
Transplant Proc; 2000 Nov; 32(7):1730-2. PubMed ID: 11119910
[No Abstract] [Full Text] [Related]
14. Clinical experience with Prograf (tacrolimus, FK 506) in Chinese patients after renal transplantation.
Yu L; Wang Y; Fu SJ; Cheng XJ
Transplant Proc; 2000 Nov; 32(7):1709-10. PubMed ID: 11119902
[No Abstract] [Full Text] [Related]
15. Long-term results of living kidney transplantation under tacrolimus immunosuppression: a single-center experience.
Tanabe K; Ishikawa N; Tokumoto T; Takahashi K; Kanematsu A; Kitani R; Fuchinoue S; Oshima T; Yagisawa T; Toma H
Transplant Proc; 1998 Jun; 30(4):1224-6. PubMed ID: 9636497
[No Abstract] [Full Text] [Related]
16. Effects of cyclosporine-tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2/3, lipoprotein a1/b, and other lipid parameters.
Seymen P; Yildiz M; Türkmen MF; Titiz MI; Seymen HO
Transplant Proc; 2009 Dec; 41(10):4181-3. PubMed ID: 20005364
[TBL] [Abstract][Full Text] [Related]
17. Conversion to tacrolimus in hyperlipidemic patients.
Friemann S; Stopp K; Christ B; Weimer R; Padberg W; Ernst W
Transplant Proc; 1999 Nov; 31(7A):41S-43S. PubMed ID: 10576042
[No Abstract] [Full Text] [Related]
18. Primary tacrolimus-based immunosuppression in renal allograft recipients: a single center experience.
Lye WC
Transplant Proc; 2000 Nov; 32(7):1700-1. PubMed ID: 11119898
[No Abstract] [Full Text] [Related]
19. Clinical experience of FK 506 for renal allograft transplantation.
Kitamura M; Hiraga S; Kobayashi D; Kakuta T; Fukuuchi F; Hida M; Satoh T
Transplant Proc; 1994 Aug; 26(4):1924-6. PubMed ID: 7520611
[No Abstract] [Full Text] [Related]
20. Results with histological diagnosis in kidney transplant rejections treated with 15-deoxyspergualin.
Kyo M; Ichikawa Y; Hanafusa T; Fukunishi T; Nagano S; Takahara S; Kokado Y; Okuyama A; Ihara H; Ito K; Sagawa S; Sonoda T; Akiyama T; Kurita T; Suzuki S; Amemiya H
Transplant Proc; 1996 Apr; 28(2):910-1. PubMed ID: 8623457
[No Abstract] [Full Text] [Related]
[Next] [New Search]
